Showing 7101-7110 of 8649 results for "".
- Melt Pharmaceuticals Doses First Patient in Phase 3 Program of MELT-300 Opioid-Free Sedationhttps://modernod.com/news/melt-pharmaceuticals-doses-first-patient-in-pivotal-phase-3-program-of-melt-300-opioid-free-sedation/2482312/Melt Pharmaceuticals announced that the first patient has been dosed in its phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingual
- Eversight Partners with LighTopTech to Improve Imaging Modalities for Eye Tissueshttps://modernod.com/news/eversight-partners-with-lightoptech-to-improve-imaging-modalities-for-eye-tissues/2482310/Eversight announced a 4-year partnership with LighTopTech that aims to improve imaging modalities for eye tissues in both clinical and research settings. Financial terms of the deal were not disclosed. As part of th
- New World Medical Receives 510(k) Clearance for KDB GLIDE Expanded Indication for Reduction of IOPhttps://modernod.com/news/new-world-medical-receives-510k-clearance-for-kdb-glide-expanded-indication-for-reduction-of-iop/2482290/New World Medical has announced it has received FDA 510(k) clearance for KDB (Kahook Dual Blade) GLIDE to be used for the reduction of IOP in adult patients with primary open-angle glaucoma (POAG) during cataract surgery or as a standalone procedure. The FDA’s
- Clearside Biomedical Publishes Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS) Injectionhttps://modernod.com/news/clearside-biomedical-publishes-consensus-guidelines-for-drug-delivery-via-suprachoroidal-space-scs-injection/2482288/Clearside Biomedical announced that new guidelines that represent best practices for injection into the suprachoroidal space have been published in "RETINA, The Journal of Retinal and Vitreous Diseases." The publication, entitled, “Suprachoroidal Space Injection Techniqu
- New Research Reveals COVID-19 Virus Could Damage Visionhttps://modernod.com/news/new-research-reveals-covid-19-virus-could-damage-vision/2482285/Researchers at the University of Missouri School of Medicine have discovered the virus that causes COVID-19 can breach the blood-retinal barrier with potential long-term consequences in the eye. Using a humanized ACE2 mice model, research led by Pawan Kumar Singh, PhD, an assi
- Drug Farm Gets Green Light from FDA to Initiate Phase 1b Trial of DF-003 in ROSAH Syndrome Patientshttps://modernod.com/news/drug-farm-gets-green-light-from-fda-to-initiate-phase-1b-trial-of-df-003-in-rosah-syndrome-patients/2482284/The FDA has cleared Drug Farm's investigational new drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) synd
- Ocugen Completes Dosing of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST Gene Therapyhttps://modernod.com/news/ocugen-completes-dosing-of-subjects-with-stargardt-disease-in-cohort-2-of-phase-12-gardian-clinical-trial-of-ocu410st-gene-therapy/2482280/Ocugen announced that dosing is complete in the second cohort of its phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment. "The completion of dosing for Cohort 2 par
- Participants of Experimental CRISPR Gene Editing Trial See Vision Improvehttps://modernod.com/news/participants-of-experimental-crispr-gene-editing-trial-see-vision-improve/2482277/About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine, the National Eye Institut
- EyeCRO Presents Phase 2 Results for MiDROPS Platformhttps://modernod.com/news/eyecro-presents-phase-2-results-for-midrops-platform/2482276/EyeCRO has announced that data from the first clinical application of its MiDROPS (Microemulsion Drug Ocular Penetration System) platform technology was presented by Telios Pharma at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, WA. The presentation
- iOR Partners Co-Founder and Chairman of the Board, Daniel S. Durrie, MD, Retireshttps://modernod.com/news/ior-partners-co-founder-and-chairman-of-the-board-daniel-s-durrie-md-retires/2482267/iOR Partners announced the retirement of Daniel S. Durrie, MD, as Chairman of the Board of Directors. Dr. Durrie co-founded iOR Partners, a provider of ophthalmic office-based surgery (OBS), in 2018. iOR's model provides surgeons with turnkey OBS suites and support service